Dermatophytosis Treatment Market Sees Growth Promise in Asia Pacific

San Francisco, California, October 18, 2018: The global market for dermatophytosis treatment is the focus of analysis of a recent market research report by TMR Research. The report is titled “Dermatophytosis Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025.” The report states that the market will tread on a healthy growth path over the forecast period benefitting from the rising demand for dermatophytosis treatment from an increasing pool of patients falling prey to the condition owing to weak immune systems.

Get Sample Copy of this Report @ 

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=16

The rising global population of geriatrics across the globe is also working well for the market as old people are more vulnerable to infections. Moreover, other factors leading to the increased need for dermatophytosis treatment include the rising prevalence of the condition owing to increased cases of hospital-acquired diseases and sedentary lifestyles.

Geographically, the global dermatophytosis treatment market acquires a significant share in its revenue from developed regions such as North America and Europe. Factors such as the encouraging reimbursement policies, easy availability of advanced healthcare facilities, and high awareness among the population regarding the benefits of early diagnosis and available methods to treat the condition work in favor of the dermatophytosis treatment market in these regions.

The market in Asia Pacific is also among one of the most promising regional markets and has become highly profitable owing to an increased focus and support of governments on the development of healthcare facilities, increased rate of awareness, and rising disposable incomes of the populations in emerging economies in the region. A swiftly expanding medical tourism sector in emerging countries such as China and India also present promising growth prospects before the dermatophytosis treatment market in Asia Pacific.

Read Comprehensive Overview of Report @

https://www.tmrresearch.com/dermatophytosis-treatment-market

Some of the leading companies operating in the global dermatophytosis treatment market are Sun Pharmaceutical Industries Limited, Novartis AG, NB Therapeutics, Inc., Quinnova Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KgaA, Tinea Pharmaceuticals, Valeant Pharmaceuticals International, Inc., AmDerma Pharmaceuticals, LLC, and Perrigo Company plc.

Increasing Cases of Dermatophyte Infections to Fuel Demand for Dermatophytosis Treatment

With the increasing prevalence of various types of fungal infections, the market for dermatophytosis treatment is observing a strong growth across the world. Dermatophytosis is caused by a fungus, called dermatophytes, which belongs to a family of organisms that can easily break down the keratin in nails, epidermis, hooves and horns, and epidermis. Dermatophytosis generally develops through direct contact with infected wounds and infected shoes, towels, or shower stalls. Drug makers are actively working on developing a highly efficient treatment for this fungus infection.

In this blog post, researchers at TMR Research are answering some of the important queries regarding the global dermatophytosis treatment market:

What are the key factors that are influencing the global market for dermatophytosis treatment?

The increasing population base of individuals with weak immune systems is the main factor behind the growth of the global dermatophytosis treatment market. Since the immune system weakens with age, the constantly increasing geriatric population has surfaced as the key contributor to this market. Apart from this, the rising sedentary lifestyle and the augmenting prevalence of hospital-acquired infections (HAIs) are also resulting in a higher rate of dermatophytosis, driving the demand for dermatophytosis treatment.

On the flip side, the dearth of awareness regarding dermatophytosis and several related diseases and their treatment options may limit the growth prospects of this market in the near future. The reluctance among patients in going for the treatment of dermatophytosis may also hamper the growth of this market, worldwide, over the next few years.

Get Sample Copy of this Report @

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=16

Which of the regional markets is likely to dominate the worldwide dermatophytosis treatment market?

Presently, North America is dominating the global market for dermatophytosis treatment, with Europe trailing closely. Availability of favorable reimbursement coverage, presence of immensely developed healthcare infrastructure, greater healthcare spending, higher awareness among people regarding dermatophytosis and the benefits of early diagnosis and treatment, and the ample availability of advanced healthcare facilities are the main factors that has been supporting the markets for dermatophytosis treatment in North America and Europe. Both the regional markets are likely to remain on the top over the next few years.

Which are the most popular strategies that players are adopting in the global market?

Novartis, Quinnova Pharmaceuticals, Tinea Pharmaceuticals, Sun Pharmaceuticals, NB Therapeutics, Valeant Pharmaceuticals, AmDerma Pharmaceuticals, Merz Pharma, and Perrigo are some of the leading players in the global market for dermatophytosis treatment. These players are aggressively focused towards offering advanced and highly effective treatment options for dermatophytosis. They are likely to get increasingly involved into strategic collaborations, specifically mergers and acquisitions to strengthen their position in this market.

Dermatophytosis Treatment Market : Production & Consumption Professional Survey Report 2025


Global Dermatophytosis Market: Snapshot

Dermatophytosis is an infectious disease caused by fungi known as dermatophytes. This fungus belong to a family of organisms that can break down the keratin in epidermis, nails, horns and hooves, epidermis, and nails. Mostly thriving in soil and involved in soil decomposition, these fungi can infect living hosts as well.

Dermatophytosis has unique features. Firstly, the disease is present only on the skin’s keratin and it feeds on keratin for nutrition. However, the presence of the fungus on the skin and its metabolic products causes an allergic reaction in the host. It can affect a host of body parts. This includes the scalp, groin, feet, bearded skin of the face, and the nails. The symptom of Dermatophytosis vary from mild inflammations to severe vesicular reactions.

Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=16

Dermatophytosis develops either through direct contact with infected wounds or indirectly through infected towels, shoes, or shower stalls. The combination of slight hot weather and tight clothing is conducive for the fungus to thrive.

Topical antifungal creams such as clotrimazole, miconazole, and terbinafine are effective for treating simple forms of Dermatophytosis that is located in parts other than the scalp. The treatment involves cleansing the affected region and rubbing cream on the skin thoroughly.

If the nature of the disease is serious it requires a prescribed line of treatment. This includes prescription drugs along with home care to prevent the infection from spreading. Home care includes avoiding clothing that discomforts the infected area, clean and dry the skin regularly, and wash beddings and clothes daily until the infection is completely clear.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=16

Dermatophytosis Treatment Market: Overview

Dermatophytosis is a fungal infection of the skin caused by a fungi that feeds on keratin, a material found in the outer layer of the skin, nails, and hair. Dermatophytosis is commonly referred to as ringworm and affects both humans and animals.

Common symptoms of dermatophytosis include itching, redness, and dryness of the infected area, separation of the nail from the nail bed, scaling, nail dystrophy, broken hair, hair loss, rashes, and nail discoloration. People with weak immune systems and those who play contact sports are at a higher risk of dermatophytosis. The skin condition is known to worsen during the summer with increased symptoms during the winters.

Read Comprehensive Overview of Report@ https://www.tmrresearch.com/dermatophytosis-treatment-market

Dermatophytosis Treatment Market: Segmentation

On the basis of diagnosis, the global dermatophytosis treatment market is classified into woods test, microscopic test, culture test, and others. By way of drugs used, the market is segmented into Imidazole, Econazole, Clotrimazole, Miconazole, Ketoconazole, Terbinafine, Clotrimazole, Corticosteroid, Terbinafine, Itraconazole, Griseofulvin, and others. Geographically, the dermatophytosis treatment market is segmented as North America, Europe, Asia Pacific, and the Rest of the World (RoW).

Dermatophytosis Treatment Market: Drivers and Restraints

One of the key factors driving the need for dermatophytosis treatment is an increasing population of people with weak immune systems. The immune system weakens with age and a globally rising geriatric population contributing to the high prevalence of dermatophytosis. Apart from this, rising sedentary lifestyle and increasing incidence of hospital-acquired diseases have resulted in a higher rate of dermatophytosis. This has driven the demand for dermatophytosis treatment.

On the other hand, the lack of awareness about dermatophytosis and related diseases, and its treatment options limits the growth prospects of this market. In addition, reluctance on the part of patients in receiving dermatophytosis treatment is restraining the growth of the market globally.

Dermatophytosis Treatment Market: Geographical Assessment

From a geographical standpoint, North America presently dominates the global dermatophytosis treatment market, with Europe coming in second. Favorable reimbursement coverage, the availability of immensely developed healthcare infrastructure, a high rate of awareness regarding dermatophytosis, greater healthcare spending, the availability of advanced healthcare facilities, and increased awareness about the benefits of early diagnosis and treatment of dermatophytosis are some of the major factors driving the North America and Europe markets for dermatophytosis treatment.

Asia Pacific possesses high growth potential in the global dermatophytosis treatment market and is likely to witness strong progress in the near future. A rapidly rising literacy rate, improving healthcare infrastructure, a rise in government support to improve healthcare facilities, and growing healthcare spending are some of the key drivers in the Asia Pacific region. The dermatophytosis treatment market in India and China is expected to grow swiftly owing to rapidly developing medical tourism in these countries. Japan is also expected to contribute to the expansion of the dermatophytosis treatment market in Asia with increased focus of the government to offer improved and advanced healthcare facilities to its citizens.

Brazil, Mexico, and Argentina are some of the key countries in the Rest of the World (RoW) segment expected to demonstrate promising growth in the dermatophytosis treatment market.

Dermatophytosis Treatment Market: Key Contributors

There are a number of players operating in the global dermatophytosis treatment market. These include Novartis AG, Quinnova Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, Tinea Pharmaceuticals, NB Therapeutics, Inc., AmDerma Pharmaceuticals, LLC, Valeant Pharmaceuticals International, Inc., Merz Pharma GmbH & Co. KgaA, Perrigo Company plc. In addition to these, there are several research institutes and universities collaborating with drug manufacturing companies for conducting clinical trials to develop effective dermatophytosis treatment methods. Some of the key contributors are the University of Minnesota, Karolinska Institute, Katholieke Universiteit Leuven, Eastern Virginia Medical School, Kurdistan University of Medical Sciences, the Department of Health, South Africa, Jamaica Hospital Medical Center, the University of Alabama at Birmingham, The Children’s Mercy Hospital, and Oita University.

Shift towards Sedentary Lifestyles to Fuel Demand for Dermatophytosis Treatment

San Francisco, California, July 06, 2017: A market intelligence report by TMR Research, titled “Dermatophytosis Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025,” offers a detailed evaluation of the trends and opportunities in the market. The report serves with a 360-degree view of the global dermatophytosis treatment market by providing insights into all important aspects, including diagnosis type, drug type, regional segmentation, and vendor landscape.

The widening pool of patients with weak immune systems is one of the primary factors augmenting the need for dermatophytosis treatment. The rapidly growing global population of geriatrics is also stoking the growth of the market, since immune system weakens with aging. Moreover, changing lifestyles play a pivotal role in the development of the dermatophytosis treatment market. People are shifting to sedentary routines, which include minimum physical activities, thereby hampering their immune systems. The increasing incidence of hospital-acquired diseases are resulting in higher rate of dermatophytosis, thereby providing a fillip to the market.

On the other hand, the lack of awareness about dermatophytosis results in a large section of patient pool remaining undiagnosed and untreated. This, in turn, limits the market from realizing its utmost potential. Additionally, reluctance on patients’ part in receiving dermatophytosis treatment is impeding the upward rise of the global market.

Geographically, North America and Europe will account for a large cumulative share in the global arena. The growth of these regions can be attributed to favorable reimbursement framework, the presence of advanced healthcare infrastructure, and rising healthcare spending. The increasing awareness among the populace regarding the merits of early diagnosis and treatment of dermatophytosis is also one of the primary factors contributing to the growth of the regions.

Asia Pacific offers immense growth opportunities to the global dermatophytosis treatment market. Developing healthcare infrastructure owing to the increasing efforts by governments is providing a significant push to the market in the region. China and India are poised to be sights of high growth rates during the forecast period, due to the rising awareness regarding dermatophytosis treatment among the populace. In Latin America, Argentina and Brazil will be the primary revenue contributors to the market.

The majority of key players in the global dermatophytosis treatment market are entering into collaborations with research institutes and universities for conducting clinical trials to develop effective treatment methods. Some of the prominent participants in the market are Novartis AG, Sun Pharmaceutical Industries Limited, Quinnova Pharmaceuticals Inc., NB Therapeutics Inc., Tinea Pharmaceuticals, Valeant Pharmaceuticals International Inc., AmDerma Pharmaceuticals LLC, Perrigo Company plc., and Merz Pharma GmbH & Co. KgaA.